THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 18, 2006--Amgen (NASDAQ:AMGN - News): Amgen (NASDAQ:AMGN - News), the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, open-label head-to-head study evaluating 200 mcg of Aranesp® (darbepoetin alfa) administered every two weeks versus 40,000 U of Epoetin alfa dosed once a week have been published in the May 20th issue of The Journal of Clinical Oncology. The study demonstrated that Aranesp dosed every two weeks resulted in similar clinical efficacy as Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.
